iShares Self-Driving EV and Tech vs State Street SPDR S&P Biotech ETF — how do they compare? iShares Self-Driving EV and Tech trades at $33.26 (market cap $264.50M), while State Street SPDR S&P Biotech ETF trades at $153.62 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 38.2× iShares Self-Driving EV and Tech's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares Self-Driving EV and Tech nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Self-Driving EV and Tech for 73 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| IDRV | XBI | |
|---|---|---|
Market Cap | $264.50M | $10.11B |
Volume | 48,021 | 12,903,266 |
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $45.48 | $169.55 |
52-Week Low | $32.68 | $104.99 |
Typical Hold Time | 73 Days | 38 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Trailing returns across standard periods
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →